| Domain | Key facts | Quantitative data | Best supporting sources |
|---|---|---|---|
| Identifiers | Fallopian tube cancer is commonly managed as part of the combined clinical entity of ovarian/fallopian tube/primary peritoneal cancers in major guidelines and pathology protocols; MeSH term available for Fallopian Tube Neoplasms. | MeSH: D005185; MONDO noted in Open Targets as fallopian tube cancer MONDO_0002158 and fallopian tube neoplasm MONDO_0021092. | (pqac-00000012, pqac-00000013, pqac-00000016, pqac-00000000) |
| Synonyms | Frequently used related names include primary fallopian tube cancer (PFTC), fallopian tube carcinoma, tubal carcinoma, and high-grade serous carcinoma of tubal origin; many HGSCs are classified with ovarian/peritoneal counterparts. | No single frequency estimate provided. | (pqac-00000004, pqac-00000010, pqac-00000014) |
| Etiology/Risk | Strong hereditary risk from BRCA1/2 and other homologous-recombination genes; current model supports distal/fimbrial tubal origin of many HGSCs through precursor lesions (p53 signature → STIL → STIC → HGSC). Ovulatory follicular fluid, ROS, and DNA damage are implicated mechanistically. Postmenopausal status, family history, elevated CA125, and abnormal TVUS are reported risk indicators. | Germline pathogenic variants in ~13.5% of EOC patients; lifetime ovarian/tubal/peritoneal cancer risk BRCA1 ~35–45%, BRCA2 ~10–20%; STIC prevalence <0.1% general population and ~2.3% in high-risk women. | (pqac-00000008, pqac-00000006, pqac-00000041, pqac-00000045, pqac-00000048) |
| Protective | Tubal sterilization, bilateral salpingo-oophorectomy, and opportunistic/prophylactic salpingectomy are associated with reduced ovarian/fallopian tube cancer risk; oral contraceptives and tubal ligation were associated with reduced type 2 ovarian cancer risk in PLCO-derived analyses. | RRSO reduces EOC risk by ~80–96% when performed within guideline ages; UKCTOCS hysterectomy with adnexal conservation showed 0.55% ovarian/tubal cancer incidence vs 0.59% with intact uterus (no significant difference). | (pqac-00000033, pqac-00000031, pqac-00000030, pqac-00000005) |
| Key phenotypes | Typical presentation includes vaginal discharge, abnormal uterine bleeding, pelvic/abdominal pain, adnexal/pelvic mass; classic Latzko triad is uncommon. Tubes are often enlarged and sausage-like on imaging; disease may be asymptomatic in precursor stages. | Latzko triad in ~10%; 87–97% of lesions unilateral; mean tumor size ~5 cm. | (pqac-00000004, pqac-00000001) |
| Molecular/Genes | Molecular hallmarks center on TP53 abnormalities and homologous-recombination deficiency. BRCA1/2, RAD51C/D, BRIP1, PALB2 are inherited susceptibility genes. STIC diagnosis uses abnormal p53 pattern and elevated Ki-67; PAX8 is typically positive and calretinin negative in HGSC lineage. Proteomic/lipidomic lesion markers include CAVIN1, EMILIN2, FBLN5, FBL, PHGDH and specific phospholipids. | STIL Ki-67 ~10–40%; abnormal Ki-67 in STIC workup >10%; serous papillary histology ~80%, endometrioid ~7%, clear cell ~2%. | (pqac-00000003, pqac-00000004, pqac-00000008, pqac-00000041, pqac-00000043, pqac-00000045, pqac-00000046) |
| Diagnostics | Diagnosis relies on pathology plus imaging and biomarkers. SEE-FIM is recommended for complete tubal examination, especially fimbria. STIC requires cytologic atypia with abnormal p53 IHC and raised proliferation. CA-125 and transvaginal ultrasound are used clinically but may be normal in STIC. MRI/US can show enlarged irregular cystic "sausage-like" tubes with papillary projections and vascularity. | In one report, unique tubal lesions in 6.3% of high-risk cases; clinically occult cancer at bilateral salpingo-oophorectomy 2.6%; CA-125 may be normal in all STIC cases in some series. | (pqac-00000003, pqac-00000001, pqac-00000034, pqac-00000048) |
| Epidemiology/Prognosis | Rare malignancy that likely has been historically under-recognized due to reclassification with tubo-ovarian HGSC. In elderly SEER cohort it represented a small fraction of gynecologic cancers. Early-stage prognosis is better with lymphadenectomy; stage, grade, and histology are key prognostic factors. Isolated STIC carries measurable long-term risk of later HGSC/peritoneal carcinoma. | PFTC ~0.14–1.8% of female genital malignancies; 1,971/112,192 (1.8%) of elderly gynecologic cancers in one SEER study; early-stage PFTC 3-/5-year CSS 91.1%/86.1% and OS 88.0%/81.3%; with lymphadenectomy CSS 93.0%/88.7% and OS 90.8%/85.4%; without lymphadenectomy CSS 87.2%/80.7% and OS 82.4%/72.9%; isolated STIC in BRCA carriers progressed to primary peritoneal cancer in 4.5%; subsequent HGSC risk 10.5% at 5 years and 27.5% at 10 years vs 0.3% and 0.9% without STIC. | (pqac-00000017, pqac-00000018, pqac-00000019, pqac-00000001) |
| Treatment | Standard management follows epithelial ovarian cancer pathways: surgical staging/cytoreduction plus platinum-taxane chemotherapy; neoadjuvant chemotherapy with interval debulking is used when upfront complete cytoreduction is not feasible. PARP inhibitor maintenance is central, especially for BRCA-mutated/HRD tumors; bevacizumab remains an anti-angiogenic option; mirvetuximab soravtansine is used for FRα-high platinum-resistant disease. | PARP maintenance examples: SOLO-1 3-year freedom from progression/death 69% vs 35%; 7-year survival 67% vs 46%; PRIMA HRD subgroup median PFS 21.9 vs 10.4 months; mirvetuximab ORR ~32–38% in SORAYA-era data. | (pqac-00000007, pqac-00000021, pqac-00000022, pqac-00000023, pqac-00000024, pqac-00000027, pqac-00000028) |
| Prevention | No screening strategy has shown mortality reduction in average-risk populations. UKCTOCS found no significant ovarian/tubal cancer mortality benefit for multimodal screening or ultrasound despite more early-stage detection with multimodal screening. Primary prevention relies on RRSO in high-risk carriers and increasing uptake of opportunistic salpingectomy; delayed oophorectomy strategies are under prospective study to reduce menopause burden. | UKCTOCS follow-up ~16.3 years with no mortality reduction; RRSO age windows BRCA1 35–40, BRCA2 40–45, RAD51C/D or BRIP1 45–50; progression from STIC to invasive cancer estimated ~7 years. | (pqac-00000031, pqac-00000035, pqac-00000033, pqac-00000001) |
| Models | Current research models emphasize fallopian tube–origin HGSC biology using 3D suspension spheroids, fallopian tube epithelium organoids, patient-derived organoids, organotypic omentum/peritoneum co-cultures, microfluidic chips, and CRISPR-engineered mouse oviduct/OSE organoids. These systems recapitulate dormancy, autophagy, adhesion, mesothelial clearance, microenvironment interactions, and patient-specific drug response. | No single prevalence metric; review highlights multiple complementary 3D model classes and short-term PDO/drug-avatar applications. | (pqac-00000049, pqac-00000050, pqac-00000051, pqac-00000052, pqac-00000053, pqac-00000055, pqac-00000056) |


*Table: This table summarizes key disease characteristics of fallopian tube cancer for knowledge-base use, including identifiers, etiology, phenotypes, molecular features, diagnostics, epidemiology, treatment, prevention, and models. It only includes facts supported by evidence retrieved in the conversation and points to the best supporting context IDs for each domain.*